226 related articles for article (PubMed ID: 27460638)
1. Impact of body mass index (BMI) on the prognosis of high-risk early breast cancer (EBC) patients treated with adjuvant chemotherapy.
Gennari A; Amadori D; Scarpi E; Farolfi A; Paradiso A; Mangia A; Biglia N; Gianni L; Tienghi A; Rocca A; Maltoni R; Antonucci G; Bruzzi P; Nanni O
Breast Cancer Res Treat; 2016 Aug; 159(1):79-86. PubMed ID: 27460638
[TBL] [Abstract][Full Text] [Related]
2. Time to initiation of adjuvant chemotherapy in patients with rapidly proliferating early breast cancer.
Farolfi A; Scarpi E; Rocca A; Mangia A; Biglia N; Gianni L; Tienghi A; Valerio MR; Gasparini G; Amaducci L; Faedi M; Baldini E; Rubagotti A; Maltoni R; Paradiso A; Amadori D
Eur J Cancer; 2015 Sep; 51(14):1874-81. PubMed ID: 26206258
[TBL] [Abstract][Full Text] [Related]
3. Obesity is an independent prognostic factor of decreased pathological complete response to neoadjuvant chemotherapy in breast cancer patients.
Karatas F; Erdem GU; Sahin S; Aytekin A; Yuce D; Sever AR; Babacan T; Ates O; Ozisik Y; Altundag K
Breast; 2017 Apr; 32():237-244. PubMed ID: 27318645
[TBL] [Abstract][Full Text] [Related]
4. Effect of obesity on disease-free and overall survival in node-positive breast cancer patients in a large French population: a pooled analysis of two randomised trials.
Ladoire S; Dalban C; Roché H; Spielmann M; Fumoleau P; Levy C; Martin AL; Ecarnot F; Bonnetain F; Ghiringhelli F
Eur J Cancer; 2014 Feb; 50(3):506-16. PubMed ID: 24315625
[TBL] [Abstract][Full Text] [Related]
5. Identifying good prognosis group of breast cancer patients with 1-3 positive axillary nodes for adjuvant cyclophosphamide, methotrexate and 5-fluorouracil (CMF) chemotherapy.
Lin YC; Chen SC; Chang HK; Hsueh S; Tsai CS; Lo YF; Hwang TL; Chen MF
Jpn J Clin Oncol; 2005 Sep; 35(9):514-9. PubMed ID: 16199422
[TBL] [Abstract][Full Text] [Related]
6. Prognostic Significance of VEGFC and VEGFR1 mRNA Expression According to HER2 Status in Breast Cancer: A Study of Primary Tumors from Patients with High-risk Early Breast Cancer Participating in a Randomized Hellenic Cooperative Oncology Group Trial.
Linardou H; Kalogeras KT; Kronenwett R; Alexopoulou Z; Wirtz RM; Zagouri F; Scopa CD; Gogas H; Petraki K; Christodoulou C; Pavlakis K; Koutras AK; Samantas E; Patsea H; Pectasides D; Bafaloukos D; Fountzilas G
Anticancer Res; 2015 Jul; 35(7):4023-36. PubMed ID: 26124351
[TBL] [Abstract][Full Text] [Related]
7. Prognostic importance of thymidylate synthase expression in early breast cancer.
Pestalozzi BC; Peterson HF; Gelber RD; Goldhirsch A; Gusterson BA; Trihia H; Lindtner J; Cortés-Funes H; Simmoncini E; Byrne MJ; Golouh R; Rudenstam CM; Castiglione-Gertsch M; Allegra CJ; Johnston PG
J Clin Oncol; 1997 May; 15(5):1923-31. PubMed ID: 9164203
[TBL] [Abstract][Full Text] [Related]
8. Differential Benefit of Adjuvant Docetaxel-Based Chemotherapy in Patients With Early Breast Cancer According to Baseline Body Mass Index.
Desmedt C; Fornili M; Clatot F; Demicheli R; De Bortoli D; Di Leo A; Viale G; de Azambuja E; Crown J; Francis PA; Sotiriou C; Piccart M; Biganzoli E
J Clin Oncol; 2020 Sep; 38(25):2883-2891. PubMed ID: 32614702
[TBL] [Abstract][Full Text] [Related]
9. The effect of body mass index on overall and disease-free survival in node-positive breast cancer patients treated with docetaxel and doxorubicin-containing adjuvant chemotherapy: the experience of the BIG 02-98 trial.
de Azambuja E; McCaskill-Stevens W; Francis P; Quinaux E; Crown JP; Vicente M; Giuliani R; Nordenskjöld B; Gutiérez J; Andersson M; Vila MM; Jakesz R; Demol J; Dewar J; Santoro A; Lluch A; Olsen S; Gelber RD; Di Leo A; Piccart-Gebhart M
Breast Cancer Res Treat; 2010 Jan; 119(1):145-53. PubMed ID: 19731015
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant chemotherapy in early breast cancer.
Ejlertsen B
Dan Med J; 2016 May; 63(5):. PubMed ID: 27127018
[TBL] [Abstract][Full Text] [Related]
11. Postoperative CMF Does Not Ameliorate Poor Outcomes in Women With Residual Invasive Breast Cancer After Neoadjuvant Epirubicin/Docetaxel Chemotherapy.
Promberger R; Dubsky P; Mittlböck M; Ott J; Singer C; Seemann R; Exner R; Panhofer P; Steger G; Bergen E; Gnant M; Jakesz R; Bago-Horvath Z; Rudas M; Bartsch R
Clin Breast Cancer; 2015 Dec; 15(6):505-11. PubMed ID: 26195436
[TBL] [Abstract][Full Text] [Related]
12. Early start of adjuvant chemotherapy may improve treatment outcome for premenopausal breast cancer patients with tumors not expressing estrogen receptors. The International Breast Cancer Study Group.
Colleoni M; Bonetti M; Coates AS; Castiglione-Gertsch M; Gelber RD; Price K; Rudenstam CM; Lindtner J; Collins J; Thürlimann B; Holmberg S; Veronesi A; Marini G; Goldhirsch A
J Clin Oncol; 2000 Feb; 18(3):584-90. PubMed ID: 10653873
[TBL] [Abstract][Full Text] [Related]
13. Clinical relevance of vascular endothelial growth factor and thymidine phosphorylase in patients with node-positive breast cancer treated with either adjuvant chemotherapy or hormone therapy.
Gasparini G; Toi M; Miceli R; Vermeulen PB; Dittadi R; Biganzoli E; Morabito A; Fanelli M; Gatti C; Suzuki H; Tominaga T; Dirix LY; Gion M
Cancer J Sci Am; 1999; 5(2):101-11. PubMed ID: 10198732
[TBL] [Abstract][Full Text] [Related]
14. Obesity is an independent prognostic variable in colon cancer survivors.
Sinicrope FA; Foster NR; Sargent DJ; O'Connell MJ; Rankin C
Clin Cancer Res; 2010 Mar; 16(6):1884-93. PubMed ID: 20215553
[TBL] [Abstract][Full Text] [Related]
15. Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer.
Gasparini G; Barbareschi M; Doglioni C; Palma PD; Mauri FA; Boracchi P; Bevilacqua P; Caffo O; Morelli L; Verderio P
Clin Cancer Res; 1995 Feb; 1(2):189-98. PubMed ID: 9815973
[TBL] [Abstract][Full Text] [Related]
16. Obesity as an independent risk factor for decreased survival in node-positive high-risk breast cancer.
Scholz C; Andergassen U; Hepp P; Schindlbeck C; Friedl TW; Harbeck N; Kiechle M; Sommer H; Hauner H; Friese K; Rack B; Janni W
Breast Cancer Res Treat; 2015 Jun; 151(3):569-76. PubMed ID: 25962694
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant chemotherapy in 780 patients with early breast cancer: 10-year data from Saudi Arabia.
Ibrahim EM; Ezzat AA; Rahal MM; Raja MM; Ajarim DS
Med Oncol; 2005; 22(4):343-52. PubMed ID: 16260851
[TBL] [Abstract][Full Text] [Related]
18. Improved outcome of high-risk early HER2 positive breast cancer with high CXCL13-CXCR5 messenger RNA expression.
Razis E; Kalogeras KT; Kotoula V; Eleftheraki AG; Nikitas N; Kronenwett R; Timotheadou E; Christodoulou C; Pectasides D; Gogas H; Wirtz RM; Makatsoris T; Bafaloukos D; Aravantinos G; Televantou D; Pavlidis N; Fountzilas G
Clin Breast Cancer; 2012 Jun; 12(3):183-93. PubMed ID: 22607768
[TBL] [Abstract][Full Text] [Related]
19. Impact of body mass index on survival in women receiving chemotherapy for early breast cancer.
Pezo RC; Chan KKW; Mata DGMM; Menjak I; Eisen A; Trudeau M
Breast Cancer Res Treat; 2022 Nov; 196(2):329-339. PubMed ID: 36114940
[TBL] [Abstract][Full Text] [Related]
20. Effect of Tailored Dose-Dense Chemotherapy vs Standard 3-Weekly Adjuvant Chemotherapy on Recurrence-Free Survival Among Women With High-Risk Early Breast Cancer: A Randomized Clinical Trial.
Foukakis T; von Minckwitz G; Bengtsson NO; Brandberg Y; Wallberg B; Fornander T; Mlineritsch B; Schmatloch S; Singer CF; Steger G; Egle D; Karlsson E; Carlsson L; Loibl S; Untch M; Hellström M; Johansson H; Anderson H; Malmström P; Gnant M; Greil R; Möbus V; Bergh J;
JAMA; 2016 Nov; 316(18):1888-1896. PubMed ID: 27825007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
